RT Journal Article
SR Electronic
T1 Mapping genetic determinants of 184 circulating proteins in 26,494 individuals to connect proteins and diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.03.21261494
DO 10.1101/2021.08.03.21261494
A1 Erin Macdonald-Dunlop
A1 Lucija Klarić
A1 Lasse Folkersen
A1 Paul R.H.J. Timmers
A1 Stefan Gustafsson
A1 Jing Hua Zhao
A1 Niclas Eriksson
A1 Anne Richmond
A1 Stefan Enroth
A1 Niklas Mattsson-Carlgren
A1 Daria V. Zhernakova
A1 Anette Kalnapenkis
A1 Martin Magnusson
A1 Eleanor Wheeler
A1 Shih-Jen Hwang
A1 Yan Chen
A1 Andrew P Morris
A1 Bram Prins
A1 Urmo Võsa
A1 Nicholas J. Wareham
A1 John Danesh
A1 Johan Sundstrom
A1 Bruna Gigante
A1 Damiano Baldassarre
A1 Rona J. Strawbridge
A1 Harry Campbell
A1 Ulf Gyllensten
A1 Chen Yao
A1 Daniela Zanetti
A1 Themistocles L. Assimes
A1 Per Eriksson
A1 Daniel Levy
A1 Claudia Langenberg
A1 J. Gustav Smith
A1 Tõnu Esko
A1 Jingyuan Fu
A1 Oskar Hansson
A1 Åsa Johansson
A1 Caroline Hayward
A1 Lars Wallentin
A1 Agneta Siegbahn
A1 Lars Lind
A1 Adam S. Butterworth
A1 Karl Michaëlsson
A1 James E. Peters
A1 Anders Mälarstig
A1 Peter K. Joshi
A1 James F. Wilson
YR 2021
UL http://medrxiv.org/content/early/2021/08/05/2021.08.03.21261494.abstract
AB We performed the largest genome-wide meta-analysis (GWAMA) (Max N=26,494) of the levels of 184 cardiovascular-related plasma protein levels to date and reported 592 independent loci (pQTL) associated with the level of at least one protein (1308 significant associations, median 6 per protein). We estimated that only between 8-37% of testable pQTL overlap with established expression quantitative trait loci (eQTL) using multiple methods, while 132 out of 1064 lead variants show evidence for transcription factor binding, and found that 75% of our pQTL are known DNA methylation QTL. We highlight the variation in genetic architecture between proteins and that proteins share genetic architecture with cardiometabolic complex traits. Using cis-instrument Mendelian randomisation (MR), we infer causal relationships for 11 proteins, recapitulating the previously reported relationship between PCSK9 and LDL cholesterol, replicating previous pQTL MR findings and discovering 16 causal relationships between protein levels and disease. Our MR results highlight IL2-RA as a candidate for drug repurposing for Crohn’s Disease as well as 2 novel therapeutic targets: IL-27 (Crohn’s disease) and TNFRSF14 (Inflammatory bowel disease, Multiple sclerosis and Ulcerative colitis). We have demonstrated the discoveries possible using our pQTL and highlight the potential of this work as a resource for genetic epidemiology.Competing Interest StatementOutside the submitted work J.D reports grants, personal fees and non-financial support from Merck Sharp & Dohme (MSD), grants, personal fees and non-financial support from Novartis, grants from Pfizer and grants from AstraZeneca outside the submitted work. J.D sits on the International Cardiovascular and Metabolic Advisory Board for Novartis (since 2010); the Steering Committee of UK Biobank (since 2011); the MRC International Advisory Group (ING) member, London (since 2013); the MRC High Throughput Science 'Omics Panel Member, London (since 2013); the Scientific Advisory Committee for Sanofi (since 2013); the International Cardiovascular and Metabolism Research and Development Portfolio Committee for Novartis; and the Astra Zeneca Genomics Advisory Board (2018). O.H has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche. P.K.J is a consultant to Humanity, Inc., a company developing direct-to-consumer measures of biological ageing and an advisor to Global Gene Corp, a company developing direct-to-consumer and business-to-business genomic solutions. A.S.B reports grants outside of this work from AstraZeneca, Biogen, BioMarin, Bioverativ, Merck, Novartis, Pfizer and Sanofi and personal fees from Novartis. J.E.P has received travel and accommodation expenses and hospitality from Olink to speak at Olink-sponsored academic meetings. E.M.D has received travel and accommodation expenses and hospitality from Olink to speak at Olink-sponsored academic meetings.Funding StatementJ.F.W. and C.H, acknowledge support from the MRC Human Genetics Unit programme grant "Quantitative traits in health and disease" (U.MC_UU_00007/10). The work of L.K. was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). E.M.D. acknowledges the MRC Doctoral Training Programme in Precision Medicine (MR/N013166/1). RJS is supported by a UKRI Innovation- HDR-UK Fellowship (MR/S003061/1). Participants in the INTERVAL randomised controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported field work and other elements of the trial. DNA extraction and genotyping were co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The academic coordinating centre for INTERVAL was supported by core funding from the: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge BRC (BRC-1215-20014). This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. COSM-C and SMCC have been supported by grants from the Swedish Research Council (grant no 2002-6147, 2005-6662, 2005-8214, 2008-2202, 2011-02427, 2015-03257, 2017-00644, 2017-06100 and 2019-01291, grants from the Swedish Research Council for Health, Working Life and Welfare (https://forte.se/en/; grant numbers 2011-0346, and 2017-00721), and annual grants from Avtal om Läkarutbildning och Forskning (ALF; Agreement concerning Cooperation on Medical Education and Research) between Uppsala University and Uppsala County Council. We acknowledge the national research infrastructure SIMPLER for provisioning of facilities and experimental support. SIMPLER receives funding through the Swedish Research Council under the grant no 2017-00644. The computations were performed on resources provided by the Swedish National Infrastructure for Computing's support for sensitive data SNIC-SENS through the Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX). SNIC is financially supported by the Swedish Research Council. The Orkney Complex Disease Study (ORCADES) was supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), a Royal Society URF to J.F.W., the MRC Human Genetics Unit quinquennial programme "QTL in Health and Disease", Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). EPIHEALTH was funded by the Swedish research council. The ARISTOTLE trial (ClinicalTrials.gov Identifier: NCT00412984) was funded by Bristol-Myers Squibb Co., Princeton, NJ, USA, and Pfizer Inc., New York, NY, USA. The computations were enabled by resources provided by the Swedish National Infrastructure for Computing (SNIC) at Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) partially funded by the Swedish Research Council through grant agreement no. 2018-05973 (project sens2017573). This work was supported by the Swedish Foundation for Strategic Research (project RB13-0197). For the BioFINDER study, work at the authors' research center was supported by several sources, including the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg foundation (2017-0383 and WCMM Fellowship for NMC 2019-2022), The Medical Faculty at Lund University and Region Skåne (WCMM Fellowship for NMC 2019-2022), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932), the Swedish Brain Foundation (FO2019-0326, FO2020-0275), The Parkinson foundation of Sweden (1280/20), the Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2020-0314), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020 NMC), the Bundy Academy (Stora Priset 2020 NMC) and the Swedish federal government under the ALF agreement (2018-Projekt0279, 2018-Projekt0054). The CROATIA-Vis study was funded by grants from the Medical Research Council (UK), from the Republic of Croatia Ministry of Science, Education and Sports (108-1080315-0302; 216-1080315-0302) and the Croatian Science Foundation (8875). The NSPHS was funded by the Foundation for Strategic Research (UG) and the European Commission FP6 (UG). Sequencing was funded by the Science for Life Laboratory, Swedish Genomes Program, which has been made available by support from the Knut and Alice Wallenberg Foundation. This work was also funded by the Swedish Medical Research Council (2019-01497) and the Swedish Heart-Lung foundation (nr. 20200687). Protein measurements were carried out by Olink Proteomics AB in Uppsala, Sweden and sequencing was performed by NGI (National Genomics Infrastructure), Stockholm, Sweden. The computations were performed on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under projects sens2016007. IMPROVE was supported by the European Commission (Contract number: QLG1- CT- 2002- 00896), Ministero della Salute Ricerca Corrente, Italy, the Swedish Heart-Lung Foundation, the Swedish Research Council-project 8691 and 0593, the Foundation for Strategic Research, the Stockholm County Council-project 562183, the Foundation for Strategic Research, the Academy of Finland-Grant #110413 and the British Heart Foundation-RG2008/008. ULSAM and PIVUS were supported by the Uppsala University Hospital. The Fenland Study (10.22025/2017.10.101.00001) is funded by the Medical Research Council (MC_UU_12015/1). We further acknowledge support for genomics from the Medical Research Council (MC_PC_13046). The ASAP study was supported by the Swedish Research Council [12660]; the Swedish Heart-Lung Foundation [20180451]; the Stockholm County Council [20180072]; and a donation by Fredrik Lundberg. Estonian Biobank analyses were funded by EU H2020 grant 692145, Estonian Research Council Grants PRG1291 and MOBTP108, European Union through the European Regional Development Fund Project SLTMR16142T, MP1GI18418R, SLTMR16142T, ERA-CVD grant MOBERA21. This investigation includes data From the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine. This project has been funded in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92019D00031. D.V.Z. was supported by Netherlands Organization for Scientific Research (NWO-VENI grant 194.006). J.F. was supported by the Dutch Heart Foundation IN-CONTROL (CVON2018-27), the ERC Consolidator grant (grant agreement No. 101001678), NWO-VICI grant VI.C.202.022, and the Netherlands Organ-on-Chip Initiative, an NWO Gravitation project (024.003.001) funded by the Ministry of Education, Culture and Science of the government of The Netherlands. The genotyping of MPP-RES was supported by grants to J.G.S. from the Swedish Heart-Lung Foundation (2016-0134 and 2016-0315), the Swedish Research Council (2017-02554), the European Research Council (ERC-STG-2015-679242), the Crafoord Foundation, Skåne University Hospital, Scania County, governmental funding of clinical research within the Swedish National Health Service, a generous donation from the Knut and Alice Wallenberg foundation to the Wallenberg Center for Molecular Medicine in Lund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study involved meta-analysis of pQTL summary statistics from 18 cohorts. The details of the IRBs/ethics committees and approvals for these individual studies are as follows. 1) ARISTOTLE: Ethical approval: Approval by the appropriate ethics committees was obtained at all sites as described in Granger et al N Engl J Med 2011; 365:981-992. DOI: 10.1056/NEJMoa1107039. 2) ASAP. Ethical approval: by the ethics committee of the Karolinska Institute (application numbers 02 to 147 and 2006/784 to 31/1). 3) BIOFINDER. Ethical approval: The Regional Ethics Committee in Lund, Sweden, approved the study design. 4) COSM cohort. Ethical approval: the Regional Ethical Review Board in Stockholm, Sweden, approved this study. 5) EGCUT. Ethical approval: approved by the Estonian Committee on Bioethics and Human Research (1.1-12/624) and by the Research Ethics Committee of the University of Tartu (application number 262/T-3, October 2016). 6) EPIHEALTH. Ethical approval: the Ethics Committee of Uppsala University (Log. No. 2010/402) and the Swedish Data Inspection Board (No. 307-2011) approved this study. 7) FENLAND. Ethical approval: the study was approved by the Cambridge Local Research Ethics Committee. 8) FHS. Ethical approval: reviewed by the Boston University Medical Center Institutional Review Board. 9) IMPROVE. Ethical approval: The study was designed in accordance with the rules of Good Clinical Practice (GCP), and with the ethical principles established in the Declaration of Helsinki. Each participant provided two different informed consents; one for general participation in the study and one for genotyping. 10) INTERVAL. Ethical approval: approved by the UK National Research Ethics Service approved the study (reference 11/EE/0538). 11) LIFELINES. Ethical approval: approved by the ethics committee of the University Medical Centre Groningen. 12) MPP-RES. Ethical approval: approved by Ethics Committee of Lund University, Sweden. 13) The NSPHS study. Ethical approval: the study was approved by the local ethics committee at the Uppsala University (Regionala Etikprovningsnamnden, Uppsala Dnr 2005:325). 14) ORCADES. Ethical approval: approved by the Research Ethics Committees in Orkney, Aberdeen (North of Scotland REC), and South East Scotland REC, NHS Lothian approved the study(reference: 12/SS/0151). 15) PIVUS. Ethical approval: approved by the Ethics Committee of the University of Uppsala. 16) The Swedish Mammography Cohort (SMCC). Ethical approval was given by the regional research ethics board at Karolinska Insitutet, Sweden. 17) ULSAM. Ethical approval: The Ethics Committee of the Faculty of Medicine at Uppsala University, Sweden, approved the study. 18) VIS. Ethical approval: the ethics committee of the Sisters of Mercy University Hospital in Zagreb, Croatia, approved the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMeta-analyses summary statistics will be made publicly available upon publication. METAL software for meta-analysis is available from http://csg.sph.umich.edu/abecasis/metal/download/. SMR-HEIDI is available from https://cnsgenomics.com/software/smr/#Download. The Coloc R package is available from https://github.com/chr1swallace/coloc.